chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from an administrative assistant concerning more than three female patients, ages 13 and up, who, on an unspecified dates, were vaccinated with a dose of Gardasil.  Subsequently, the patients exhibited signs of becoming lightheaded.  The administrative assistant reported that it would be impossible to determine the number of patients exhibiting these signs and she could not provide a lot number for the vaccine.  The office had decided to start a journal logging the patients affected and lot numbers of the vaccine.  At the time of this report, the outcomes were unknown.  Additional information is not expected.
Chills; severe diarrhea; vomiting; nausea; dizziness; This is a spontaneous report from a contactable consumer (patient). A 64-year-old female patient received BNT162B2 (solution for injection, Lot number: EK9231), administered in left arm via an unspecified route of administration on 03Feb2021 at single dose for covid-19 immunisation. Medical history included High blood pressure, strabismus, known allergies Sulfa antibiotics, quinolone antibiotics. The patient was not diagnosed with COVID-19 prior to vaccination. The patient was not tested for COVID-19 post vaccination. Historical vaccine included BNT162B2 First dose: lot EJ1686, expiry Mar2021, 0.3ml single dose by injection once to left arm for covid-19 immunisation. Concomitant medications included Atorvastatin 20mg, amlodipine-benazepril 2.5-10 taken for an unspecified indication. The patient experienced chills, severe diarrhea, vomiting, nausea, dizziness on 03Feb2021 23:00. The outcome of the events was recovering. Treatment received for the adverse events as nausea medication.  Follow-up activities are completed. No further information is expected.
got dizzy; felt queasy; Temp was lightly elevated; Sore injection site; Could not sleep, very uncomfortable.; Got hot and sweaty about 3 1/2 hours after shot.; Got hot and sweaty about 3 1/2 hours after shot.; administration_date=26Jan2021; other vaccine date = 26Jan2021; administration_date=26Jan2021; other vaccine date = 26Jan2021; This is a spontaneous report from a contactable consumer (patient). A 63-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: unknown) via an unknown route of administration on left arm (L shoulder/Arm) on 26Jan2021 at 09:00 AM at the age of 63 years old at a single dose for COVID-19 immunization. Patient was not pregnant at the time of vaccination. Medical history included RA (Rheumatoid arthritis), Penicillin allergy and covid-19 (The patient was diagnosed with COVID-19 prior to vaccination). Concomitant medications included leflunomide (ARAVA) at 20mg, once a day, daily vitamins and mesalamine 1/day. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination. Also reported administration date 26Jan2021; other vaccine date 26Jan2021. On 26Jan2021 09:00, the patient experienced sore injection site (shot was given very high on L shoulder/Arm). Felt like a sharp pain when given. Got hot and sweaty about 3 and an half hours after shot. Could not sleep, very uncomfortable. Next morning (on 27Jan2021), the patient was getting ready to eat breakfast and got dizzy and felt queasy. Temp was lightly elevated. Taking Tylenol to help control soreness. The patient assessed the events as non-serious. No treatment was received in response to the adverse event. Since the vaccination, the patient hasn't been tested for COVID-19. The outcome of the events administration_date=26Jan2021; other vaccine date = 26Jan2021 was unknown and patient was recovering from all other events.  Information on the lot/batch number has been requested.
This case was reported by a healthcare professional and described the occurrence of raised area injection site in a subject of unspecified age (18 to 60 years of age) and gender who was vaccinated with BOOSTRIX (GlaxoSmithKline). In January 2012 (either the 17th or the 18th) the subject inadvertently received a dose of BOOSTRIX intradermally. This was wrong vaccine administered and inappropriate route of vaccination. The subject should have received a ppd skin test. BOOSTRIX should be administered intramuscularly when ordered. Within the same week of receiving BOOSTRIX (on or prior to 20 January 2012) the subject experienced redness, raised, pain and itching at the site of injection. The outcome of the events was unknown at the time of reporting. It was reported BOOSTRIX was inadvertently administered intradermally to 7 subjects instead of the ppd skin test. It was noted that the subjects were roughly between the ages of 18 to 60 years. Two of the subjects were males and the rest were females. One subject reported redness, raised, pain and itching at the site of injection (this case A0962818A). Three subjects reported no adverse event and no additional information was known regarding the other 3 subjects. Additional linked cases include A0962809A, A0962813A, A0962814A, A0962815A, A0962816A and A0962817A. Follow-up information was received for this case on 08 February 2012. It was reported that the subject was a 21 year old female. Injection site reaction including redness, raised area, pain and itching at the site of injection with onset of 17 January 2012 were noted. Per previous reported information vaccination with BOOSTRIX occurred on the 17th or 18th of January 2012. Given the onset of events was 17 January 2012, administration of BOOSTRIX should have occurred on the same day of event onset, 17 January 2012. Resolution from a single dose vial inadvertently and intradermally instead of tuberculin purified protein derivative. No significant medical history was reported. Seasonal contraceptive an ibuprofen were taken concurrently.
Passed out for 30 seconds, fever, chills, fatigue. Ambulance called, minor concussion suffered.
Information has been received from a physician concerning a couple that came into the office and one of them in 2007 (a few months ago) was vaccinated with a dose of Zostavax (Oka/Merck) and one did not, "afterwards the couple kissed in the mouth" and the next day the spouse that did not receive the vaccine presented with shingles on their face. The patient sought unspecified medical attention. At the time of the report the patient's status was unknown. A product quality complaint was not involved. A product quality complaint was not involved. No further information is available.
Tired; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP) for a Pfizer sponsored program. The reporter is the patient.  A 58-year-old male patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1, Manufacturer Unknown), for COVID-19 Immunization. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "Tired".  Additional information: Tired after getting second dose of Comirnaty and did get the Omicron variant after being vaccinated. The reporter considered that event was caused by suspect vaccine.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
c/o pain & swelling, redness @ inj site;site warm;complete ROM w/o diff;4cm induration by 5 cm induration;
pt recv vax 18JUL95 & 20JAN98 pt devel 18 pox w/o fever;the case considered mild;24JAN98 pt had recovered;
Mom reports that patient developed a fever of 104.4 per forehead scanner thermometer 14 hours after given hep A vaccine & INFLUENZA.
Approximately 2 days post vax, the pt experienced an ear infection and pneumonia. The pt was treated with antibiotics and Augmentin in breathing treatment but was not hospitalized. The pt continues on breathing treatments. She also said her niece had similar bout with pneumonia after being administered Prevnar.
adipose necrosis 1x1<less;pt exp dimpling of thigh p/vax;dimpling is a result of necrosis of fatty tissue;
Patient was in monitoring station after receiving her Moderna vaccine. Patient was crying, stating "My tongue is numb." Patient was evaluated by provider, FNP. Brought patient inside to clinic exam room. Patient's husband and baby present. Patient verbalized she could breathe "fine" but just that her "tongue is numb" and continued to cry. Respirations, circulation within normal limits. Administered Diphenhydramine 50mg 0.5ml IM into left deltoid per provider's orders. Patient tolerated well. Observed for 35 minutes in exam room. Provided calming measures, drinking water, cool compress. Patient calm and verbalized felt better before leaving. Instructed patient to go to ER if having difficulty breathing.
The vaccine was administered on the following date: 1/12/21 and at approximately the following time: 3:50PM   The symptoms began 20-25 min after administration of the vaccine.  The symptoms were: Chest tightness and dizziness that is moving up to her throat - similar to shellfish allergy reaction. Vitals all stable.  No rash, no wheezing on exam, no facial or tongue edema.  She was sent to the ED where she was treated with Tylenol, famotidine and methylprednisolone with resolution of symptoms.
Hospitalized;  COVID-19 positive (9.11.21);  fully vaccinated  Admission Date: 9/11/2021 Discharge Date: 9/15/21 Discharge Disposition:  home health care DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Dizziness Weakness COVID-19 HOSPITAL COURSE: Patient is a 52-year-old female with a history of PE on Eliquis, prior TIA, chronic obstructive pulmonary disease, SVT on beta-blocker and antiarrhythmic who presented with dizziness.  She had a recent admission from 09/02-9/5 due to poor oral intake along with multiple electrolyte abnormalities, hypotension and hypoalbuminemia.  Her electrolytes were replaced and she also received thiamine, folate and multivitamin due to history of chronic alcohol use and was discharged home with home care. She presented due to dizziness and was found to be positive for COVID-19.  She was not hypoxic.  She was not a candidate for remdesivir or Decadron.  She did receive monoclonal antibodies on 09/12.  Due to her ongoing dizziness, MRI of the brain was obtained which did not reveal any acute pathology. Patient continued to remain hypotensive and was on flecainide 100 mg twice a day as well as Toprol XL 150 mg daily in addition to methadone, Norco, tizanidine and gabapentin. She was seen by Neurology who felt that patient's dizziness could be due to hypotension, COVID infection as well as the multiple medications that she was on that could cause dizziness. She was unable to be evaluated by PT and OT due to ongoing hypotension but this resolved and PT recommended home with home health care. .  Amlodipine was held, Toprol XL was reduced to 25 mg daily, gabapentin was decreased to 300 mg 3 times a day and flecainide was dec. To 50 mg po bid. This was at the recommendation of cardiology.  Patient had persistent SVT during an admission in July and was seen by Cardiology and EP and placed on flecainide as well as Toprol during that time.  Cardiology has been consulted.  She has f.u. with cardiology and EP as an out patient. She was also instructed to quarantine / isolate until 9/22 and was given warning signs and symptoms that would
Treatment of COVID-19; Treatment of COVID-19; Moderna Dose Number: 4, Pfizer / BioNTech Dose Number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (BNT162B2), on 05Mar2021 as dose 1, single (Lot number: EN6199), in left arm, on 26Mar2021 as dose 2, single (Lot number: ER8727), in left arm and on 26Sep2021 as dose 3 (booster), single (Lot number: FE3592) at the age of 46 years, in left arm for covid-19 immunisation; coviD-19 vaccine nrvv MVa (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), on 18Sep2022 as dose 4 (booster), single (Lot number: AS7145B), in left arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: DEXLANSOPRAZOLE; ESTRADIOL; CITALOPRAM; MONTELUKAST; XYZAL; LEVOTHYROXINE. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 18Sep2022, outcome "unknown", described as "Moderna Dose Number: 4, Pfizer / BioNTech Dose Number: 3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: Negative tests 1 & 3 days after end of treatment; Negative, notes: Negative tests 1 & 3 days after end of treatment; Positive, notes: positive test morning of day 5 after end of treatment. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Anti-viral details: Product COVID 19 Treatment, brand=Pfizer, Treatment start date on 21Dec2022, Treatment stop date on 25Dec2022, Indication on Treatment of COVID-19.
Site red, warm, swollen, lips swollen, eyes puffy. (L) arm had rxn.
Initial information received on 11/10/06 from a health care professional. A female pt (age and date of birth not reported) received an injection of Menactra, lot number U1948AA, on 11/1/06. The route and site of administration were not reported. Within 24 to 36 hours post administration, the pt developed pneumonia and was hospitalized for five days. The pt was treated for Rocephin and Levaquin. She had a neg culture. The reporter stated that the pt had no signs or symptoms of meningitis and has recovered from the event of pneumonia. The reporter of this case is the same as for case 2006-03059, which also involves pneumonia following Menactra vaccination.
Patient states arm very red and warm over large area(not just small spot at injection site)--not getting better in last day, possibly worse?
Irregularly shaped, red rash near but below the injection site, tender but not itchy. Parasthesia in fingers, wrist, and forearm of left hand. Delayed soreness of entire left arm.
Vaccine given at younger age than recommended (was supposed to get Hep B # 3, inadvertently given Hep A) no adverse effects.
This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided. On 27-APR-2017, the patient was vaccinated with an expired dose of RECOMBIVAX HB intramuscularly, expiration date on 15-APR-2017 (strength, dose number, anatomical location and lot number were not provided) for prophylaxis. No adverse event reported. Additional information has been requested.
5-10 min after vaccines given mom stated pt vomited in bathroom.  Once out of bathroom mom stated pt feet "hot".  Temp was 99.8 axillary 15 min later temp was 101.6 - Gave 5mL children's ibuprofen checked temp - 100.0 axillary.
Swollen hands and feet; Tight sensation and discomfort in back of legs/ heaviness in my feet and lower legs; Swollen gland in right armpit; Nausea; Burning sensation in back; Pain in injection site; ''I'' have experienced tingling, tightness and heaviness in ''my'' feet and lower legs.; ''I'' also feel slightly off; Having loose stool; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 09Apr2021 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to unknown form of anxiety medication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Concomitant medications included ethinylestradiol/ norethisterone acetate (LOESTRIN), multivitamin (MANUFACTURER UNKNOWN) and loratadine (CLARITIN); all for an unknown indication from an unknown date and unknown if ongoing. On 11Apr2021, the patient experienced swollen gland in right armpit, nausea and burning sensation in back 3 days later. The patient experienced swollen hands and feet next day (12Apr2021), had tight sensation and discomfort in back of legs, pain in injection site for 2 days. For the last 2 weeks and at the time of reporting, the patient experienced tingling, tightness and heaviness in her feet and lower legs. She also felt slightly off and had loose stool. Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pain in injection site was resolved on an unknown date in Apr2021, after a duration of 2 days; while that of the tight sensation and discomfort in back of legs/ heaviness in my feet and lower legs, tingling feet, swollen gland in right armpit, nausea, burning sensation in back, swollen hands and feet, also feel slightly off and had loose stool was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Dizziness and headache a few hours after vaccine administered. Next day headache and vomiting. Arm is red hot and inflamed with large welt approximately 10 inches in diameter. Arm welt was larger 2 days after receiving vaccine. Arm is painful and difficult to move.
During the monitoring  after the vaccine, I began feeling weak and lightheaded,  The dr and nurse sat with me and gave a nutrition bar and OJ but the symptoms got worse so I was laid down but still the symptoms felt as if they got worse got worse. So I was transported to the ED with a bad headache.  I was monitored for about an hour and was released to go home.  While at home I had severe weakness, body aches, nauseaed and sleep about 14 hours the next day.  And for about the next 3 or 4 days I had mild symptoms but I could still work and by 12/25 all symptoms had subsided and I have been ok every since.
Initial report was received on 10 January 2013 from a consumer who is also the patient's daughter. A female patient (date of birth not reported) had received a "standard dose" of Influenza vaccine (manufacturer, lot number, route and site of administration not reported) in "late August or early September". The patient was admitted to the hospital on 10 January 2013 and tested positive for influenza. No further information was available at the time of the report. The patient's outcome was not reported. Documents held by sender: none.
Pt indicated her arm began hurting immediately after receiving the vaccine. She inquired with the pharmacist about taking NSAID and he advised waiting 24 hours.  Pt indicated arm continued to hurt for 24 hours.  At 7PM on 10/09/2012, patient began to experience severe achiness, and all over joint pain, headache and nausea. On 10-10-12 at 12:15pm patient took 200mg Ibuprofen. She indicated symptoms subsided about an hour later.  Indicated she received influenza vaccine annually and never experienced these symptoms in the past.
Enlarged Lymph nodes showed up on annual mammogram in Oct 2022. Ultrasound done, Biopise done in Nov 2022. Test results said a reactionary cause to swollen nodes.  In Jan 2023, lymph nodes were swollen enough to cause discomfit in left arm. Swollen state much more obvious. Ultrasound schechuled for Mar 16th.
24 hour fever; chills; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a 64-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (on eyelid, forehead and scalp two years ago from the reporting date, at the age of 62 years) and eye swelling. Previously administered products included shingrix with an associated reaction of pyrexia (1st dose received on an unknown date, reference case US2021AMR039283).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced fever and chills. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the fever and chills were recovered/resolved.   It was unknown if the reporter considered the fever and chills to be related to Shingrix.  Additional details were provided as follows: The patient had reported the case for herself/himself. The patient had the old shot and she/he did not understand at first why her/his eye was so swollen. The patient got it treated fast and it was not very painful. The age at vaccination was not reported. The patient received Shingrix shot which gave her/him 24 hour fever and chills and she/he stated that it was so far so good. The follow-up would not possible, as no contact details were available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR039283:Same reporter
On first day, patient was feeling tired, dizzy and foggy and 18 hours later was found dead on the floor.
Arm sore at injection site; Hot to touch at injection site; Knot at injection site; Slight fatigue; Joint pain worse than normal; Occasional headache; This is a spontaneous report from a contactable nurse (patient). A 42-year-old female patient (non-pregnant) received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EL3248), via an unspecified route of administration in left arm, on 12Jan2021 at 10:30, at a single dose, for COVID-19 immunization. The patient's medical history included rheumatoid arthritis, eczema, depression, anxiety, slipped disc in back, overweight, and allergies to sulfa and latex. The patient had unspecified concomitant medications. The patient previously took the first dose of BNT162B2 (Lot Number: EJ1685) on 21Dec2020 (10:00 AM), for COVID-19 immunization (left arm). The patient was not diagnosed with COVID-19 prior vaccination. No other vaccine was administered in four weeks. The vaccine was administered in a hospital facility. On 13Jan2021 at 4 AM, the patient experienced arm sore, hot to touch, and knot at injection site; slight fatigue; joint pain was worse than normal; and occasional headache. No treatment was administered for the events. The patient has not been tested for COVID-19 post-vaccination. The patient had not recovered from the events.
Around 2 AM, roughly 14 hours after receiving Covid Modena vaccine (1st dose) I woke up in a violent shaking situation.  I could not stop shaking, it was more than just the ?chills? I thought my teeth were going to break they were so tough. It made me hyperventilate because I was so worked up , almost like I couldn?t catch my breath from body being so tense from shaking.  This lasted all night, around 8 am, the ?shakes? became less severe and I then felt like it was a 100 degrees, sweating ALOT.  This lasted all day.  Saturday my body hurt so badly, my muscles and joints hurt so much it hurt to move my toes, I cried and cried and I am a very tough person but this was not normal by any means.  By Sunday I was feeling somewhat better but I wouldn?t and won?t go through this again , my arm still feels like an elephant was sitting on it.  I understand your body makes reactions to vaccines because it recognizes it and is preparing it for antibodies to be made but this was not a normal situation , so much I am almost positive I will not take the second dose, nobody knows how I felt and I will say honestly , this was a horrible and scary thing.
"I had a hard lump at the very site of the shot, very red and very hot to touch. Its now 10/21 and still like that but less. Its never happened before and I've had the shots before. It was a fairly hard lump and about 3 Inch diameter".